2022 AACR Annual Meeting Update
The 2022 AACR meeting featured pancreatic cancer research in artificial intelligence, screening and earlier detection, and vaccines.
Cherishing the Simple Things
Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.
New Immunotherapy Strategy Aimed at High-Risk Population
Dr. Neeha Zaidi is the lead investigator of an immunotherapy trial using a vaccine for people at high risk for pancreatic cancer.
A Report from ASCO GI 2022
Clinical trials were reported on at ASCO GI 2022, as well as reports on COVID, virtual tumor boards, and racial disparities in treatment.
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
Evaluating Different Immunotherapy Combinations
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
Claudin May Be the Next Big Target in Pancreatic Cancer Treatment
While immunotherapy and other targeted treatments involving monoclonal antibodies have been successful in other cancers, pancreatic cancer has been notoriously tough to target because of a lack of suitable cell surface targets to which the antibodies can bind. But a new target has been identified, and researchers are hopeful that an investigational drug that homes…
Two New Immunotherapy Trials Aim to Make Therapy More Effective
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
A Vaccine To Boost Immune Response to Pancreatic Cancer
Researchers are testing whether a vaccine can heighten the body’s immune response to pancreatic cancer after surgical removal of the tumor.
Triple Immunotherapy Shows Dramatic Results
Dr. William Freed-Pastor is testing a combination of three types of immunotherapy to attack pancreatic tumors.